Le Lézard16h
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...
Merck stock price target cut to $115 at Guggenheim
Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...
Medscape21h
Lymphoma Expert Blends Bedside and Trial Work
New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.
The Sign Your Common Cold Could Be A Deadly Cancer; Know Other Symptoms of Lymphoma
This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...
Doctors enroll patients in trial for aggressive blood cancer
Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...
Melanoma stage determines treatment plan: Advice from an expert
While melanoma is much less common than other types of skin cancer, it is the most serious because it is more likely to ...
Lung cancer cells can go 'off grid' and develop their own electrical network within the tumor, study shows
Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...
Frontiers21h
Exploring Small Molecule Inhibitors in Cancer, Inflammation, and Autoimmune Disorders
Given the success of the previous Research Topic 'Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases', we are pleased to ...